Rana Al-Hallaq

Rana Al-Hallaq, PhD is Executive Director and Partner at Pfizer Ventures. Rana leverages her preclinical, clinical, and business development experience to assess, invest in, and manage equity investments for Pfizer Ventures. She currently has responsibility for Pfizer’s investments in ReCode Therapeutics (Menlo Park, CA; Dallas, TX), Vivet Therapeutics (Paris, France), Mitokinin (San Francisco, CA), Autifony Therapeutics (Stevenage, UK), Blade Therapeutics (South San Francisco, CA), RefleXion Medical (Hayward, CA), Montis (Leuven, Belgium), Biograph55 (San Francisco, CA), Jnana Therapeutics (Boston, MA), Triplet Therapeutics (Cambridge, MA), Arkuda (Cambridge, MA), and the Dementia Discovery Fund (London, UK). Prior to her current role, Rana was a Transactionalist in Worldwide Business Development at Pfizer where she was responsible for negotiating and transacting licenses, acquisitions, and partnerships across therapeutic areas. Rana joined Pfizer in 2015 as an Early Candidate Clinical Lead where she advised early clinical programs in CNS to ensure alignment with business strategies.